EP1246804A1 - 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor - Google Patents
4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitorInfo
- Publication number
- EP1246804A1 EP1246804A1 EP00971662A EP00971662A EP1246804A1 EP 1246804 A1 EP1246804 A1 EP 1246804A1 EP 00971662 A EP00971662 A EP 00971662A EP 00971662 A EP00971662 A EP 00971662A EP 1246804 A1 EP1246804 A1 EP 1246804A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- crystal
- formula
- trιfluoromethyl
- recited
- dιhydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 102
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title abstract description 4
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 title abstract description 4
- OXMLOGDTDJEBJR-UHFFFAOYSA-N (2-ethyl-1,2,3,4-tetrahydroquinolin-4-yl)carbamic acid Chemical compound C1=CC=C2NC(CC)CC(NC(O)=O)C2=C1 OXMLOGDTDJEBJR-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 80
- 241000124008 Mammalia Species 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 239000003937 drug carrier Substances 0.000 claims description 29
- 239000003085 diluting agent Substances 0.000 claims description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 28
- 239000003981 vehicle Substances 0.000 claims description 26
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims description 24
- 201000001320 Atherosclerosis Diseases 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 15
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 15
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 12
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 12
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 12
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 11
- 208000008589 Obesity Diseases 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- 208000037487 Endotoxemia Diseases 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 206010021024 Hypolipidaemia Diseases 0.000 claims description 9
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 9
- 206010063837 Reperfusion injury Diseases 0.000 claims description 9
- 208000006011 Stroke Diseases 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 208000010125 myocardial infarction Diseases 0.000 claims description 9
- 208000037803 restenosis Diseases 0.000 claims description 9
- 230000002792 vascular Effects 0.000 claims description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 208000031225 myocardial ischemia Diseases 0.000 claims description 7
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 6
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 238000009499 grossing Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims 3
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 2
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 2
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 2
- 239000010685 fatty oil Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 10
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 10
- 208000029078 coronary artery disease Diseases 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 8
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 8
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- -1 cholesteryl ester Chemical class 0.000 description 7
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940125753 fibrate Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 3
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 229960005370 atorvastatin Drugs 0.000 description 3
- 229920000080 bile acid sequestrant Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229960003765 fluvastatin Drugs 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229960002965 pravastatin Drugs 0.000 description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- MVODTGURFNTEKX-UHFFFAOYSA-N 2-bromo-n-(2-bromoethyl)-n-(thiophen-2-ylmethyl)ethanamine;hydrobromide Chemical compound Br.BrCCN(CCBr)CC1=CC=CS1 MVODTGURFNTEKX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- YGBQZFPEMRCQRY-UHFFFAOYSA-N benzyl n-ethenylcarbamate Chemical compound C=CNC(=O)OCC1=CC=CC=C1 YGBQZFPEMRCQRY-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- AZFYCLSCZLWMBW-PWSUYJOCSA-N ethyl (2r,4s)-4-amino-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound FC(F)(F)C1=CC=C2N(C(=O)OCC)[C@H](CC)C[C@H](N)C2=C1 AZFYCLSCZLWMBW-PWSUYJOCSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000207 pro-atherogenic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Definitions
- This invention relates to cholesteryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)- cholesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycendes and accordingly to treat diseases which are affected by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycendes, such as atherosclerosis and cardiovascular diseases in certain mammals (i.e., those which have CETP in their plasma), including humans.
- CETP cholesteryl ester transfer protein
- this invention relates to CETP inhibitor crystals, pharmaceutical compositions comprising these crystals, a process for preparing these crystals and to methods of treating atherosclerosis, obesity, and related diseases and/or conditions with the crystals.
- Atherosclerosis and its associated coronary artery disease is the leading cause of mortality in the industrialized world.
- CAD coronary artery disease
- CHD coronary heart disease
- LDL-cholesterol may be the most recognized form of dyslipidemia, it is by no means the only significant lipid associated contributor to CHD.
- Low HDL-cholesterol is also a known risk factor for CHD (Gordon, D.J., et al ,' "High-density Lipoprotein Cholesterol and Cardiovascular Disease", Circulation, (1989), 79 8-15)
- dyslipidemia is not a unitary risk profile for CHD but may be comprised of one or more lipid aberrations
- cholesteryl ester transfer protein activity affects all three.
- the net result of CETP activity is a lowering of HDL cholesterol and an increase in LDL cholesterol This effect on lipoprotein profile is believed to be pro-atherogenic, especially in subjects whose lipid profile constitutes an increased risk for CHD.
- Another aspect of this invention is directed to an anhydrous crystal of Formula
- Another aspect of this invention is directed to the corresponding anhydrous crystal having the X-ray powder diffraction pattern as shown in Figure 1
- Another aspect of this invention is directed to an ethanolate crystal of Formula I
- Another aspect of this invention is directed to the corresponding ethanolate crystal having the X-ray powder diffraction pattern as shown in Figure 2
- a preferred dosage is about 0 01 to 100 mg/kg/day of a Formula I crystal
- An especially preferred dosage is about 0 1 to 10 mg/kg/day of a Formula I crystal
- compositions, combinations and kits reference is made to a crystal of Formula I While it is understood that if the crystal is in solution, the crystal form is not present (in contrast to e g , a dry tablet formulation), the following methods pharmaceutical compositions combinations and kits are intended to include a method or formulation resulting from a use of such crystal (e.g., administering a gelatin capsule including an oil formulation solution of the crystal).
- Yet another aspect of this invention is directed to methods for treating atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypert ⁇ glyce ⁇ demia, fami al- hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being either male or female) by administering to a mammal in need of such treatment an atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypert ⁇ glyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications
- Yet another aspect of this invention is directed to a method for treating atherosclerosis in a mammal (including a human being) by administering to a mammal in need of such treatment an atherosclerosis treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating peripheral vascular disease in a mammal (including a human being) by administering to a mammal in need of such treatment a peripheral vascular disease treating amount of a Formula I crystal.
- Yet another aspect of this invention is directed to a method for treating dyslipidemia in a mammal (including a human being) by administering to a mammal in need of such treatment a dyslipidemia treating amount of a Formula I crystal.
- Yet another aspect of this invention is directed to a method for treating hyperbetalipoproteinemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hyperbetalipoproteinemia treating amount of a Formula I crystal.
- Yet another aspect of this invention is directed to a method for treating hypoalphalipoproteinemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hypoalphalipoproteinemia treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating hypercholesterolemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hypercholesterolemia treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating hypertriglyce ⁇ demia in a mammal (including a human being) by administering to a mammal in need of such treatment a hypert ⁇ glyceridemia treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating fami al-hypercholesterolemia in a mammal (including a human being) by administering to a mammal in need of such treatment a fami al- hypercholesterolemia treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating cardiovascular disorders in a mammal (including a human being) by administering to a mammal in need of such treatment a cardiovascular disorder treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating angina in a mammal (including a human being) by administering to a mammal in need of such treatment an angina treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating ischemia in a mammal (including a human being) by administering to a mammal in need of such treatment an ischemic disease treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating cardiac ischemia in a mammal (including a human being) by administering to a mammal in need of such treatment a cardiac ischemic treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating stroke in a mammal (including a human being) by administering to a mammal in need of such treatment a stroke treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating a myocardial infarction in a mammal (including a human being) by administering to a mammal in need of such treatment a myocardial infarction treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating reperfusion injury in a mammal (including a human being) by administering to a mammal in need of such treatment a reperfusion injury treating amount of a Formula I crystal.
- Yet another aspect of this invention is directed to a method for treating angioplastic restenosis in a mammal (including a human being) by administering to a mammal in need of such treatment an angioplastic restenosis treating amount of a Formula I crystal.
- Yet another aspect of this invention is directed to a method for treating hypertension in a mammal (including a human being) by administering to a mammal in need of such treatment a hypertension treating amount of a Formula I crystal
- Yet another aspect of this invention is directed to a method for treating the vascular complications of diabetes in a mammal (including a human being) by administering to a mammal in need of such treatment a vascular complications of diabetes treating amount of a Formula I crystal.
- Yet another aspect of this invention is directed to a method for treating obesity in a mammal (including a human being) by administering to a mammal in need of such treatment an obesity treating amount of a Formula I crystal.
- Yet another aspect of this invention is directed to a method for treating endotoxemia in a mammal (including a human being) by administering to a mammal in need of such treatment an endotoxemia treating amount of a Formula I crystal.
- This invention is also directed to pharmaceutical compositions which comprise a therapeutically effective amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent.
- This invention is also directed to pharmaceutical compositions for the treatment of atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyce ⁇ demia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being) which comprise a therapeutically effective amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent.
- This invention is also directed to pharmaceutical compositions for the treatment of atherosclerosis in a mammal (including a human being) which comprise an atherosclerosis treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of dyslipidemia in a mammal which comprise a dyslipidemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of hyperbetalipoproteinemia in a mammal which comprise a hyperbetalipoproteinemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of hypoalphalipoproteinemia in a mammal which comprise a hypoalphalipoproteinemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- This invention is also directed to pharmaceutical compositions for the treatment of hypercholesterolemia in a mammal (including a human being) which comprise a hypercholesterolemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- This invention is also directed to pharmaceutical compositions for the treatment of hypert ⁇ glyceridemia in a mammal (including a human being) which comprise a hypertriglyce ⁇ demia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of familial-hypercholesterolemia in a mammal which comprise a familial-hypercholesterolemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of angina in a mammal which comprise an angma treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of ischemia in a mammal which comprise an ischemic treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of cardiac ischemia in a mammal which comprise a cardiac ischemic treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- This invention is also directed to pharmaceutical compositions for the treatment of stroke in a mammal (including a human being) which comprise a stroke treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- pharmaceutical compositions for the treatment of a myocardial infarction in a mammal (including a human being) which comprise a myocardial infarction treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of reperfusion injury in a mammal which comprise a reperfusion injury treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of angioplastic restenosis in a mammal which comprise an angioplastic restenosis treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- compositions for the treatment of hypertension in a mammal which comprise a hypertension treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- This invention is also directed to pharmaceutical compositions for the treatment of the vascular complications of diabetes in a mammal (including a human being) which comprise a vascular complications of diabetes treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- pharmaceutical compositions for the treatment of obesity in a mammal (including a human being) which comprise an obesity treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
- This invention is also directed to a pharmaceutical combination composition
- a pharmaceutical combination composition comprising a therapeutically effective amount of a composition comprising a first compound, said first compound being a Formula I crystal, a second compound, said second compound being an HMG-CoA reductase inhibitor, an microsomal t ⁇ giyceride transfer protein (MTP)/Apo B secretion inhibitor, a PPAR activator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacm, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant, and/or optionally a pharmaceutical carrier, vehicle or diluent
- HMG-CoA reductase inhibitor Preferred among the second compounds are an HMG-CoA reductase inhibitor and a MTP/Apo B secretion inhibitor
- a particularly preferred HMG-CoA reductase inhibitor is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or ⁇ vastatin
- Another aspect of this invention is a method for treating atherosclerosis in a mammal comprising administering to a mammal suffering from atherosclerosis a first compound, said first compound being a Formula I crystal, and a second compound, said second compound being an HMG-CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacm, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant wherein the amounts of the first and second compounds result in a therapeutic effect
- the second compound is an HMG-CoA reductase inhibitor or an MTP/Apo B secretion inhibitor
- kits comprising a a first compound, said first compound being a Formula I crystal, and a pharmaceutically acceptable carrier in a first in a unit dosage form, b a second compound, said second compound being an HMG CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacm, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant and a pharmaceutically acceptable carrier in a second unit dosage form, and c means for containing said first and second dosage forms wherein the amounts of the first and second compounds result in a therapeutic effect
- a preferred second compound is an HMG-CoA reductase inhibitor or an MTP/Apo B secretion inhibitor
- a particularly preferred HMG-CoA reductase inhibitor is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or nvastatin
- the present invention is also directed to processes for preparing crystalline anhydrous [2R.4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2- ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester by dissolving or mixing [2R,4S] 4-[(3,5-b ⁇ s-t ⁇ fluoromethyl-benzyl)-methoxycarbonyl- am ⁇ no]-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl este
- Another aspect of this invention is directed to a process for preparing crystalline ethanolate [2R.4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl- am ⁇ no]-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester by dissolving or mixing [2R,4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl- am ⁇ no]-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester in ethanol/water at ambient temperature for about 0 5 to about 18 hours
- ethanol is used without water
- This invention is also directed to a process for preparing crystalline anhydrous [2R,4S] 4-[(3,5-b ⁇ s-t ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2-ethyl-6- t ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester comprising dissolving or mixing [2R,4S] 4-[3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl- am ⁇ no]-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester in ethanol at ambient temperature for about 2 to about 24 hours It is noted that as the anhydrous and ethanolate crystals are of different energy levels seeding with either anhydrous or ethanolate may determine the resulting isolated
- mammals is meant to refer to all mammals which contain CETP in their plasma, for example, rabbits and primates such as monkeys and humans. Certain other mammals e.g., dogs, cats, cattle, goats, sheep and horses do not contain CETP in their plasma and so are not included herein.
- ethanolate refers to an ethanol of solvation
- treating includes preventative (e.g., prophylactic) and palliative treatment.
- pharmaceutically acceptable it is meant the carrier, vehicle, diluent, excipients, and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
- reaction-inert solvent and “inert solvent” refers to a solvent or mixture of solvents which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
- the compound of this invention can exist in radiolabelled form, i.e., said compound may contain one or more atoms containing an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- Radioisotopes of hydrogen, carbon, phosphorous, fluorine and chlorine include 3 H, 1 C, 32 P, 35 S, 8 F and 36 CI, respectively.
- the compound of this invention which contains those radioisotopes and/or other radioisotopes of other atoms is within the scope of this invention.
- radiolabelled compound of this invention can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabelled compounds can be prepared by carrying out the procedures disclosed in the Examples below by substituting a readily available radiolabelled reagent for a non-radiolabelled reagent
- FIG. 1 is a characteristic x-ray powder diffraction pattern showing that anhydrous [2R,4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2- ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester is crystalline.
- Vertical Axis Intensity (CPS); Horizontal Axis. Two theta (degrees)
- FIG. 2 is the characteristic x-ray powder diffraction pattern of the ethanolate [2R.4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2-ethyl-6- tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester as crystalline Vertical Axis: Intensity (CPS); Horizontal Axis: Two theta (degrees)) Detailed Description Of The Invention
- the compound of this invention can be made by processes which include analogous processes known in the chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the compound of this invention are provided as further features of the invention and are described below including in the Examples.
- An anhydrous crystalline form of the above compound may be prepared from the amorphous compound by recrystallization from hexanes (solvent comprised of hexane isomers (e.g., n-hexane, cyclohexane, methyl pentane, etc )) at a temperature of about 40°C to about 80°C, preferably 60° followed typically by granulating, for about 2 to about 24 hours, then filtering the material and subsequent air drying.
- hexanes solvent comprised of hexane isomers (e.g., n-hexane, cyclohexane, methyl pentane, etc )
- the anhydrous crystal may be prepared from the ethanolate crystalline form (described below) utilizing analogous procedures to the immediately preceding procedure.
- the yield in this procedure may be enhanced by azeotroping the ethanol from the hexanes.
- An ethanolate crystalline form of the above compound may be prepared from the amorphous compound by recrystallization from ethanol/water at a temperature of about 20°C to about 25°C, preferably ambient temperature for about 0 5 hour to about 18 hours Typically the range is about 3% to about 10% ethanol and about 90% to about 97% water. Preferably the ratio is about 10% to about 90% ethanol/water.
- the ethanolate crystalline form may be prepared utilizing procedures analogous to those described above but using ethanol alone.
- the filtered materials are typically granulated for about 2 hours to about 24 hours followed by air drying.
- the compound of the instant invention is orally admmistrable and is accordingly used in combination with a pharmaceutically acceptable vehicle, carrier or diluent suitable to oral dosage forms.
- suitable pharmaceutically-acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
- the active compound will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described below.
- the compound may be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like.
- the pharmaceutical compositions may, if desired, contain additional components such as flavorants, sweeteners, excipients and the like
- the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin, excipients such as dicalcium phosphate, a disintegrating agent such as corn starch, potato starch, alginic acid, a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin
- a dosage unit form is a capsule, for example a gel capsule, it may contain, in addition to or instead of materials of the above type, a liquid carrier such as a fatty glyce ⁇ de or mixtures of fatty glyce ⁇ des, such as olive oil, or MiglyolTM or CapmulTM glyce ⁇ des
- Dosage forms may also include orral suspensions.
- tablets may be coated with shellac, sugar or both.
- a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor
- the compound of the instant invention may also be administered parenterally.
- parenteral administration the compound may be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
- injectable solutions prepared in this manner can then be administered intravenously, intrape ⁇ toneally, subcutaneously, or intramuscularly.
- the pharmaceutical forms suitable for injectable use include sterile solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy sy ⁇ ngability exists It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi They may be sterilized, for example, by filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, or by irradiating or heating the compositions where such irradiating or heating is both appropriate and compatible with the drug formulation.
- Additional pharmaceutical formulations may include, inter alia, suppositories, subhngual tablets, topical dosage forms and the like and these may be prepared according to methods which are commonly accepted in the art. Controlled release, sustained release, and delayed release oral or parenteral compositions may be used.
- the dosage of the compound of the instant invention which is administered will generally be varied according to principles well known in the art taking into account the severity of the condition being treated and the route of administration.
- the compound will be administered to a warm blooded animal (such as a human, livestock or pet) so that an effective dose, usually a daily dose administered in unitary or divided portions, is received, for example a dose in the range of about 0.01 to about 100 mg/kg/day body weight, preferably about 0.1 to about 10 mg/kg/day body weight.
- the above dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such deviations are within the scope of this invention
- [2R,4S]4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2-ethyl-6- t ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester was prepared in optically enriched form by resolution of the corresponding racemate, or an intermediate in its synthesis, using standard methods.
- Example 2 (1 -Benzotr ⁇ azol-1 -yl-propyl)-(4-t ⁇ fluoromethyl-phenyl)-am ⁇ ne
- benzot ⁇ azole 36.96 g, 310 mmol, 1.0 equiv
- dry toluene 400 mL
- 4-(tr ⁇ fluoromethyl)an ⁇ l ⁇ ne 39.1 mL, 310 mmol, 1.0 equiv
- 50 mL toluene was added over one minute.
- Example 3 c ⁇ s-(2-Ethyl-6-tr ⁇ fluoromethyl-1 ,2,3,4-tetrahvdro-qu ⁇ nol ⁇ n-4-yl)-carbam ⁇ c acid benzyl ester
- N-vinyl- carbamic acid benzyl ester 27.66 g, 156 mmol, 1.0 equiv
- dry toluene 500 mL
- the mixture was filtered and the solids washed 1 x 50 mL ethyl acetate.
- the filtrate was concentrated to approximately 250 mL. 500 mL toluene were added, and the mixture concentrated to approximately 500 mL. 500 mL n-heptane were added, the slurry was stirred 1 h, filtered through a Buchner funnel, and dried.
- Example 4 c ⁇ s-4-Benzyloxycarbonylam ⁇ no-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 - carboxylic acid ethyl ester
- c ⁇ s-(2- ethyl-6-tr ⁇ fluoromethyl-1 ,2,3,4-tetrahydro-qu ⁇ nol ⁇ n-4-yl)-carbam ⁇ c acid benzyl ester (96.0 g, 254 mmol, 1.0 equiv), dry dichloromethane (720 mL), and dry pyndine (103 mL, 1.27 mol, 5.0 equiv).
- Example 5 cis-4-Amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid ethyl ester
- a one liter, four neck flask under nitrogen atmosphere was charged with cis-4- benzyloxycarbonylamino-2-ethyl-6-thfluoromethyl-3,4-dihydro-2H-quinoline-1 - carboxylic acid ethyl ester (40.1 g, 89 mmol, 1.0 equiv), methanol (400 mL), and ammonium formate (14.0 g, 223 mmol, 2.5 equiv).
- Example 7 (-H2R, 4S)-4-(3,5-B ⁇ s-tr ⁇ fluoromethyl-benzylam ⁇ no)-2-ethyl-6-t ⁇ fluoromethyl-3,4- d ⁇ hydro-2H-gu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester tosylate salt (-) (2R, 4S)-4-Am ⁇ no-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester hem ⁇ -(-)-d ⁇ benzoyl-L-tartrate salt (13 0 g, 26 2 mmol, 1 0 equiv) was suspended in 1 ,2-d ⁇ chloroethane (260 mL) in a 500 mL separatory funnel.
- the mixture was washed 1 x 65 mL 1 N NaOH, 1 x 65 mL brine, and dried (MgS0 4 ).
- the mixture was filtered, concentrated to approximately approximately 80 mL, and transferred to a 250 mL three neck flask.
- 3,5-B ⁇ s(tr ⁇ fluoromethyl)benzaldehyde (4.53 mL, 27.5 mmol, 1.05 equiv) was added, and the mixture stirred 1 h at room temperature under nitrogen atmosphere.
- Sodium triacetoxyborohyd ⁇ de (11.1 g, 52.4 mmol, 2.0 equiv) was added in one portion, and the white slurry was stirred 18 h.
- Example 8 (-H2R, 4S)-4-[(3,5-B ⁇ s-t ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no1-2-ethyl-6- tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester mono ethanolate Na 2 CO 3 (s) (6.75 g, 63.7 mmol, 3.5 equiv) was added to a room temperature solution of (-)-(2R, 4S)-4-(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzylam ⁇ no)-2-ethyl-6-tr ⁇ fluoromethyl-3,4- d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester tosylate salt (13.0 g, 18.2 mmol, 1.0 equiv) in dry THF (130 m
- Methyl chloroformate (3.51 mL, 45.5 mmol, 2.5 equiv) was added neat, dropwise over 2 mm. After 24 h, the mixture was concentrated to 65 mL, diluted with 260 mL ethyl acetate, and transferred to a separately funnel. The mixture was washed 1 x 90 mL 1 N HCI (C0 2 evolution), 1 x 90 mL saturated aq. NaHCO 3 , 1 x 90 mL brine, and dried (MgSO 4 ). Filtration and concentration of filtrate afforded a clear oil, which was cost ⁇ pped 3 x 33 mL 2B ethanol.
- Example 9 Anhydrous, (-)-(2R,4S)-4-[(3,5-B ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ nol-2- ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester.
- Microscopy Well formed rods and equant (fractured rods) crystals demonstrating high birefringence when viewed across the C axis. Being in the Trigonal crystal system the crystals do not demonstrate birefringence when viewed down the C axis. The crystals demonstrate a cleavage plane perpendicular to the C axis Fusion Microsocopy In Type A oil dissolution at 50°C.
- Microscopy crystalline needles with moderate birefringence.
- Dry clear melt at 43°C NMR shows ethanol of solvation Degree of crystal nity: highly crystalline
- Hygroscopicity non-hygroscopic
- Example 11 Anhydrous (-)-(2R,4S)-4-[(3,5-b ⁇ s-tr ⁇ fluromethylbenzyl)-methoxycarbonyl-am ⁇ nol-2- ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hvdro-2H-gu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Crystalline forms of a CETP inhibitor of formula (I), methods of making the crystals, methods of using the crystals and pharmaceutically compositions containing the crystals are disclosed.
Description
4-CARBOXYAMINO-2-ETHYL-l,2,3,4-TETRAHYDROQUINOLINE CRYSTAL AS CETP INHIBITOR
Background Of The Invention This invention relates to cholesteryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)- cholesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycendes and accordingly to treat diseases which are affected by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycendes, such as atherosclerosis and cardiovascular diseases in certain mammals (i.e., those which have CETP in their plasma), including humans.
More particularly, this invention relates to CETP inhibitor crystals, pharmaceutical compositions comprising these crystals, a process for preparing these crystals and to methods of treating atherosclerosis, obesity, and related diseases and/or conditions with the crystals.
Atherosclerosis and its associated coronary artery disease (CAD) is the leading cause of mortality in the industrialized world. Despite attempts to modify secondary risk factors (smoking, obesity, lack of exercise) and treatment of dyslipidemia with dietary modification and drug therapy, coronary heart disease (CHD) remains the most common cause of death in the U.S., where cardiovascular disease accounts for 44% of all deaths, with 53% of these associated with atherosclerotic coronary heart disease
Risk for development of this condition has been shown to be strongly correlated with certain plasma lipid levels While elevated LDL-cholesterol may be the most recognized form of dyslipidemia, it is by no means the only significant lipid associated contributor to CHD. Low HDL-cholesterol is also a known risk factor for CHD (Gordon, D.J., et al ,' "High-density Lipoprotein Cholesterol and Cardiovascular Disease", Circulation, (1989), 79 8-15)
High LDL-cholesterol and triglyceπde levels are positively correlated, while high levels of HDL-cholesterol are negatively correlated with the risk for developing cardiovascular diseases Thus, dyslipidemia is not a unitary risk profile for CHD but may be comprised of one or more lipid aberrations
Among the many factors controlling plasma levels of these disease dependent principles, cholesteryl ester transfer protein (CETP) activity affects all
three. The role of this 70,000 dalton plasma glycoprotein found in a number of animal species, including humans, is to transfer cholesteryl ester and tπglycer ide between lipoprotein particles, including high density lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins (VLDL), and chylomicrons. The net result of CETP activity is a lowering of HDL cholesterol and an increase in LDL cholesterol This effect on lipoprotein profile is believed to be pro-atherogenic, especially in subjects whose lipid profile constitutes an increased risk for CHD.
No wholly satisfactory HDL-elevating therapies exist. Niacin can significantly increase HDL, but has serious toleration issues which reduce compliance. Fibrates and the HMG CoA reductase inhibitors raise HDL-C only modestly (-10-12%). As a result, there is a significant unmet medical need for a well-tolerated agent which can significantly elevate plasma HDL levels, thereby reversing or slowing the progression of atherosclerosis.
Commonly assigned U.S. application ser. No. 09/391 ,152 filed September 7, 1999 entitled 4-CARBOXYAMINO-2-SUBSTITUTED-1 ,2,3,4- TETRAHYDROQUINOLINES, the disclosure of which is hereby incorporated by reference, is directed to compounds of the following general formula:
Specifically, the compound [2R.4S] 4-[(3,5-bιs-tπfluoromethyl-benzyl)- methoxycarbonyl-amιno]-2-ethyl-6-tπfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 - carboxylic acid ethyl ester is described
Thus, although there are a variety of anti-atherosclerosis therapies, there is a continuing need and a continuing search in this field of art for alternative therapies.
Summary Of The Invention This invention is directed to a Formula I crystal
Alternatively, a crystal of the above Formula I is named as [2R,4S] 4- [(3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6- trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester
Another aspect of this invention is directed to an anhydrous crystal of Formula
Another aspect of this invention is directed to the corresponding anhydrous crystal having the X-ray powder diffraction pattern as shown in Figure 1
Another aspect of this invention is directed to an ethanolate crystal of Formula I
Another aspect of this invention is directed to the corresponding ethanolate crystal having the X-ray powder diffraction pattern as shown in Figure 2 A preferred dosage is about 0 01 to 100 mg/kg/day of a Formula I crystal An especially preferred dosage is about 0 1 to 10 mg/kg/day of a Formula I crystal
In the text herein including the following methods, pharmaceutical compositions, combinations and kits reference is made to a crystal of Formula I While it is understood that if the crystal is in solution, the crystal form is not present (in contrast to e g , a dry tablet formulation), the following methods pharmaceutical compositions combinations and kits are intended to include a method or formulation
resulting from a use of such crystal (e.g., administering a gelatin capsule including an oil formulation solution of the crystal).
Yet another aspect of this invention is directed to methods for treating atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertπglyceπdemia, fami al- hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being either male or female) by administering to a mammal in need of such treatment an atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertπglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia treating amount of a Formula I crystal.
Yet another aspect of this invention is directed to a method for treating atherosclerosis in a mammal (including a human being) by administering to a mammal in need of such treatment an atherosclerosis treating amount of a Formula I crystal Yet another aspect of this invention is directed to a method for treating peripheral vascular disease in a mammal (including a human being) by administering to a mammal in need of such treatment a peripheral vascular disease treating amount of a Formula I crystal.
Yet another aspect of this invention is directed to a method for treating dyslipidemia in a mammal (including a human being) by administering to a mammal in need of such treatment a dyslipidemia treating amount of a Formula I crystal.
Yet another aspect of this invention is directed to a method for treating hyperbetalipoproteinemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hyperbetalipoproteinemia treating amount of a Formula I crystal.
Yet another aspect of this invention is directed to a method for treating hypoalphalipoproteinemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hypoalphalipoproteinemia treating amount of a Formula I crystal
Yet another aspect of this invention is directed to a method for treating hypercholesterolemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hypercholesterolemia treating amount of a Formula I crystal Yet another aspect of this invention is directed to a method for treating hypertriglyceπdemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hypertπglyceridemia treating amount of a Formula I crystal
Yet another aspect of this invention is directed to a method for treating fami al-hypercholesterolemia in a mammal (including a human being) by administering to a mammal in need of such treatment a fami al- hypercholesterolemia treating amount of a Formula I crystal
Yet another aspect of this invention is directed to a method for treating cardiovascular disorders in a mammal (including a human being) by administering to a mammal in need of such treatment a cardiovascular disorder treating amount of a Formula I crystal
Yet another aspect of this invention is directed to a method for treating angina in a mammal (including a human being) by administering to a mammal in need of such treatment an angina treating amount of a Formula I crystal Yet another aspect of this invention is directed to a method for treating ischemia in a mammal (including a human being) by administering to a mammal in need of such treatment an ischemic disease treating amount of a Formula I crystal
Yet another aspect of this invention is directed to a method for treating cardiac ischemia in a mammal (including a human being) by administering to a mammal in need of such treatment a cardiac ischemic treating amount of a Formula I crystal
Yet another aspect of this invention is directed to a method for treating stroke in a mammal (including a human being) by administering to a mammal in need of such treatment a stroke treating amount of a Formula I crystal Yet another aspect of this invention is directed to a method for treating a myocardial infarction in a mammal (including a human being) by administering to a mammal in need of such treatment a myocardial infarction treating amount of a Formula I crystal
Yet another aspect of this invention is directed to a method for treating reperfusion injury in a mammal (including a human being) by administering to a mammal in need of such treatment a reperfusion injury treating amount of a Formula I crystal. Yet another aspect of this invention is directed to a method for treating angioplastic restenosis in a mammal (including a human being) by administering to a mammal in need of such treatment an angioplastic restenosis treating amount of a Formula I crystal.
Yet another aspect of this invention is directed to a method for treating hypertension in a mammal (including a human being) by administering to a mammal in need of such treatment a hypertension treating amount of a Formula I crystal
Yet another aspect of this invention is directed to a method for treating the vascular complications of diabetes in a mammal (including a human being) by administering to a mammal in need of such treatment a vascular complications of diabetes treating amount of a Formula I crystal.
Yet another aspect of this invention is directed to a method for treating obesity in a mammal (including a human being) by administering to a mammal in need of such treatment an obesity treating amount of a Formula I crystal.
Yet another aspect of this invention is directed to a method for treating endotoxemia in a mammal (including a human being) by administering to a mammal in need of such treatment an endotoxemia treating amount of a Formula I crystal.
This invention is also directed to pharmaceutical compositions which comprise a therapeutically effective amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent. This invention is also directed to pharmaceutical compositions for the treatment of atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceπdemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being) which comprise a therapeutically effective amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent.
This invention is also directed to pharmaceutical compositions for the treatment of atherosclerosis in a mammal (including a human being) which comprise an atherosclerosis treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent This invention is also directed to pharmaceutical compositions for the treatment of peripheral vascular disease in a mammal (including a human being) which comprise a peripheral vascular disease treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of dyslipidemia in a mammal (including a human being) which comprise a dyslipidemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of hyperbetalipoproteinemia in a mammal (including a human being) which comprise a hyperbetalipoproteinemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of hypoalphalipoproteinemia in a mammal (including a human being) which comprise a hypoalphalipoproteinemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of hypercholesterolemia in a mammal (including a human being) which comprise a hypercholesterolemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent This invention is also directed to pharmaceutical compositions for the treatment of hypertπglyceridemia in a mammal (including a human being) which comprise a hypertriglyceπdemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of familial-hypercholesterolemia in a mammal (including a human being) which comprise a familial-hypercholesterolemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of angina in a mammal (including a human being) which comprise an
angma treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of ischemia in a mammal (including a human being) which comprise an ischemic treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of cardiac ischemia in a mammal (including a human being) which comprise a cardiac ischemic treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of stroke in a mammal (including a human being) which comprise a stroke treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent This invention is also directed to pharmaceutical compositions for the treatment of a myocardial infarction in a mammal (including a human being) which comprise a myocardial infarction treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of reperfusion injury in a mammal (including a human being) which comprise a reperfusion injury treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of angioplastic restenosis in a mammal (including a human being) which comprise an angioplastic restenosis treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of hypertension in a mammal (including a human being) which comprise a hypertension treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of the vascular complications of diabetes in a mammal (including a human being) which comprise a vascular complications of diabetes treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to pharmaceutical compositions for the treatment of obesity in a mammal (including a human being) which comprise an obesity treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent This invention is also directed to pharmaceutical compositions for the treatment of endotoxemia in a mammal (including a human being) which comprise an endotoxemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
This invention is also directed to a pharmaceutical combination composition comprising a therapeutically effective amount of a composition comprising a first compound, said first compound being a Formula I crystal, a second compound, said second compound being an HMG-CoA reductase inhibitor, an microsomal tπgiyceride transfer protein (MTP)/Apo B secretion inhibitor, a PPAR activator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacm, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant, and/or optionally a pharmaceutical carrier, vehicle or diluent
Preferred among the second compounds are an HMG-CoA reductase inhibitor and a MTP/Apo B secretion inhibitor A particularly preferred HMG-CoA reductase inhibitor is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or πvastatin
Another aspect of this invention is a method for treating atherosclerosis in a mammal comprising administering to a mammal suffering from atherosclerosis a first compound, said first compound being a Formula I crystal, and a second compound, said second compound being an HMG-CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacm, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant wherein the amounts of the first and second compounds result in a therapeutic effect A preferred aspect of the above method is wherein the second compound is an HMG-CoA reductase inhibitor or an MTP/Apo B secretion inhibitor
A particularly preferred aspect of the above method is wherein the HMG-CoA reductase inhibitor is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or πvastatin
Yet another aspect of this invention is a kit comprising a a first compound, said first compound being a Formula I crystal, and a pharmaceutically acceptable carrier in a first in a unit dosage form, b a second compound, said second compound being an HMG CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacm, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant and a pharmaceutically acceptable carrier in a second unit dosage form, and c means for containing said first and second dosage forms wherein the amounts of the first and second compounds result in a therapeutic effect
A preferred second compound is an HMG-CoA reductase inhibitor or an MTP/Apo B secretion inhibitor
A particularly preferred HMG-CoA reductase inhibitor is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or nvastatin The present invention is also directed to processes for preparing crystalline anhydrous [2R.4S] 4-[(3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2- ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester by dissolving or mixing [2R,4S] 4-[(3,5-bιs-tπfluoromethyl-benzyl)-methoxycarbonyl- amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester in the presence of a suitable organic solvent, preferably hexanes
Another aspect of this invention is directed to a process for preparing crystalline ethanolate [2R.4S] 4-[(3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl- amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester by dissolving or mixing [2R,4S] 4-[(3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl- amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester in ethanol/water at ambient temperature for about 0 5 to about 18 hours Preferably ethanol is used without water
This invention is also directed to a process for preparing crystalline anhydrous [2R,4S] 4-[(3,5-bιs-tπfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6- tπfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester comprising dissolving or mixing [2R,4S] 4-[3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl- amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester in ethanol at ambient temperature for about 2 to about 24 hours
It is noted that as the anhydrous and ethanolate crystals are of different energy levels seeding with either anhydrous or ethanolate may determine the resulting isolated crystalline form As is known in the art the presence of seed crystals in the air in a lab may be sufficient "seeding." In one embodiment anhydrous crystals may be obtained using hexanes and the resulting anhydrous crystals may be used to seed the production of further anhydrous crystals from ethanol
As used herein the term mammals is meant to refer to all mammals which contain CETP in their plasma, for example, rabbits and primates such as monkeys and humans. Certain other mammals e.g., dogs, cats, cattle, goats, sheep and horses do not contain CETP in their plasma and so are not included herein.
The term ethanolate refers to an ethanol of solvation.
The term "treating", "treat" or "treatment" as used herein includes preventative (e.g., prophylactic) and palliative treatment.
By "pharmaceutically acceptable" it is meant the carrier, vehicle, diluent, excipients, and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
As used herein, the expressions "reaction-inert solvent" and "inert solvent" refers to a solvent or mixture of solvents which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
It will be recognized that the compound of this invention can exist in radiolabelled form, i.e., said compound may contain one or more atoms containing an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Radioisotopes of hydrogen, carbon, phosphorous, fluorine and chlorine include 3H, 1 C, 32P, 35S, 8F and 36CI, respectively The compound of this invention which contains those radioisotopes and/or other radioisotopes of other atoms is within the scope of this invention. Tπtiated, i.e , 3H, and carbon-14, i e , 14C, radioisotopes are particularly preferred for their ease of preparation and detectabi ty A radiolabelled compound of this invention can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabelled compounds can be prepared by carrying out the procedures disclosed in the Examples below by substituting a readily available radiolabelled reagent for a non-radiolabelled reagent
Other features and advantages will be apparent from the specification and claims which describe the invention
Brief Description of the Drawings FIG. 1 is a characteristic x-ray powder diffraction pattern showing that anhydrous [2R,4S] 4-[(3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2- ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester is crystalline. (Vertical Axis: Intensity (CPS); Horizontal Axis. Two theta (degrees))
FIG. 2 is the characteristic x-ray powder diffraction pattern of the ethanolate [2R.4S] 4-[(3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6- trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester as crystalline Vertical Axis: Intensity (CPS); Horizontal Axis: Two theta (degrees)) Detailed Description Of The Invention
In general the compound of this invention can be made by processes which include analogous processes known in the chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the compound of this invention are provided as further features of the invention and are described below including in the Examples.
The amorphous form of the compound of this invention [2R.4S] 4-[(3,5-bιs- tπfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6-tπfluoromethyl-3,4-dιhydro- 2H-quιnolιne-1 -carboxylic acid ethyl ester is prepared as disclosed below (see Example 1 ). An anhydrous crystalline form of the above compound may be prepared from the amorphous compound by recrystallization from hexanes (solvent comprised of hexane isomers (e.g., n-hexane, cyclohexane, methyl pentane, etc )) at a temperature of about 40°C to about 80°C, preferably 60° followed typically by granulating, for about 2 to about 24 hours, then filtering the material and subsequent air drying.
Alternatively, the anhydrous crystal may be prepared from the ethanolate crystalline form (described below) utilizing analogous procedures to the immediately preceding procedure. In addition, the yield in this procedure may be enhanced by azeotroping the ethanol from the hexanes. An ethanolate crystalline form of the above compound may be prepared from the amorphous compound by recrystallization from ethanol/water at a temperature of about 20°C to about 25°C, preferably ambient temperature for about 0 5 hour to about 18 hours Typically the range is about 3% to about 10% ethanol and about
90% to about 97% water. Preferably the ratio is about 10% to about 90% ethanol/water.
Alternatively, the ethanolate crystalline form may be prepared utilizing procedures analogous to those described above but using ethanol alone. The filtered materials are typically granulated for about 2 hours to about 24 hours followed by air drying.
The following Table 1 details important properties for three forms of [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trιfluoromethyl- 3, 4-dihydro-2H-quinolιne-1 -carboxylic acid ethyl ester: the amorphous (A); and the two crystalline forms ethanolate (B) and crystalline anhydrous (C).
TABLE 1
Amorphous A
1 Ethanolate B (Fig- 2)
Anhydrous C (Fig. 1 )
Loses some ethanol at closed bottle ambient conditions but remains crystalline
The compound of the instant invention is orally admmistrable and is accordingly used in combination with a pharmaceutically acceptable vehicle, carrier or diluent suitable to oral dosage forms. Suitable pharmaceutically-acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The active compound will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described below. Thus, for oral administration the compound may be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions may, if desired, contain additional components such as flavorants, sweeteners, excipients and the like The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin, excipients such as dicalcium phosphate, a disintegrating agent such as corn starch, potato starch, alginic acid, a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin When a dosage unit form is a capsule, for example a gel capsule, it may contain, in addition to or instead of materials of the above type, a liquid carrier such as a fatty glyceπde or mixtures of fatty glyceπdes, such as olive oil, or Miglyol™ or Capmul™ glyceπdes Dosage forms may also include orral suspensions.
Various other materials may be present as coatings or to modify the physical form of the dosage unit For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a
sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor
The compound of the instant invention may also be administered parenterally. For parenteral administration the compound may be combined with sterile aqueous or organic media to form injectable solutions or suspensions. The injectable solutions prepared in this manner can then be administered intravenously, intrapeπtoneally, subcutaneously, or intramuscularly.
The pharmaceutical forms suitable for injectable use include sterile solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syπngability exists It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi They may be sterilized, for example, by filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, or by irradiating or heating the compositions where such irradiating or heating is both appropriate and compatible with the drug formulation.
Additional pharmaceutical formulations may include, inter alia, suppositories, subhngual tablets, topical dosage forms and the like and these may be prepared according to methods which are commonly accepted in the art. Controlled release, sustained release, and delayed release oral or parenteral compositions may be used.
The dosage of the compound of the instant invention which is administered will generally be varied according to principles well known in the art taking into account the severity of the condition being treated and the route of administration. In general, the compound will be administered to a warm blooded animal (such as a human, livestock or pet) so that an effective dose, usually a daily dose administered in unitary or divided portions, is received, for example a dose in the range of about 0.01 to about 100 mg/kg/day body weight, preferably about 0.1 to about 10 mg/kg/day body weight. The above dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such deviations are within the scope of this invention
EXAMPLES Melting points were determined with a Thomas Hoover melting point apparatus or a DSC apparatus Unless otherwise stated, CD3CI3 was used for NMR
spectra. Microanalysis was performed by Schwarzkopf Microanalytical Laboratory. All reagents and solvents were obtained commercially and used without purification.
Example 1 c/s-4-[(3,5-Bιs-trιfluoromethyl-benzyl)-methoxycarbonyl-amιno1-2-ethyl-6- trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester:
A solution of c/s-4-(3,5-bιs-trιfluoromethyl-benzylamιno)-2-ethyl-6-trιfluoromethyl-3,4- dιhydro-2H-quino ne-1 -carboxylic acid ethyl ester (2.0 g, 3 7 mmol) and pyndine (0.58 g, 7.4 mmol) in 100 mL of dichloromethane was cooled in an ice/water bath as methyl chloroformate (0.87 g, 9.2 mmol) was added slowly. After stirring overnight at room temperature, the reaction mixture was washed twice with a 2N hydrochloric acid solution, dried over magnesium sulfate, filtered and concentrated in vacuo to afford the crude product, which was purified by silica gel chromatography using 5-10% ethyl acetate/hexanes as eluent to afford 1.8 g of the title product. MS m/z. 601 (M+ + 1 ), 1H NMR (coalescing mixture of conformers, CDCI3) δ 0.6-0.8 (bm, 3H), 1.2-1.3 (bm, 3H), 1.3-1.5 (bm, 2H), 1.6-1.75 (bm, 1 H), 2.1-2.3 (bm, 1 H), 3.7-3.9 (bs, 3H), 4.0-4.4 (bm, 4H), 5.0-5.6 (bm, 2H), 7.1 (s, 1 H), 7 4-7.6 (bm, 2H), 7.6-7.8 (bm, 3H).
[2R,4S]4-[(3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6- tπfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester was prepared in optically enriched form by resolution of the corresponding racemate, or an intermediate in its synthesis, using standard methods.
Example 2 (1 -Benzotrιazol-1 -yl-propyl)-(4-tπfluoromethyl-phenyl)-amιne A two liter, four neck flask under nitrogen atmosphere was charged with benzotπazole (36.96 g, 310 mmol, 1.0 equiv) and dry toluene (400 mL) A room temperature solution of 4-(trιfluoromethyl)anιlιne (39.1 mL, 310 mmol, 1.0 equiv) and 50 mL toluene was added over one minute. A room temperature solution of propionaldehyde (24.6 mL, 341 mmol, 1.1 equiv) and 50 mL toluene was then added over 20 minutes There was an exotherm from 23°C to 30°C during this addition After stirring 24 h, n-heptane (500 mL) was added, and the slurry stirred an additional 1 h. The suspension was filtered, the solids were washed with n-heptane (1 x 100 mL, then 1 x 200 mL, and dried (1 -Benzotπazol-1 -yl-propyl)-(4-trιfluoromethyl- phenyl)-amιne was isolated as shiny white needles (81.3 g, 82%) After 24 h, a second crop was isolated from the filtrate (8 7 g, 9%) mp 130-132 °C, 1H NMR
(DMSO-d6, 400 MHz) δ 0.82 (t, 3H, J=7.5 Hz), 2.25 (m, 2H), 6.49 (m, 1 H), 6.80 (d, 2H, J=8 7 Hz), 7.35 (m, 3H), 7.50 (m, 1 H), 7.88 (d, 1 H, J=8.3 Hz), 7 99 (m, 1 H), 8.09 (d, 1 H, J=8.5 Hz); 13C NMR (DMSO-d6, 100 MHz) δ 149.32, 146.19, 131.46, 127.73, 126.8, 125.33 (q, J=270 Hz), 124.44, 119.88, 1 18.27 (q, J=31.7 Hz), 1 12.91 , 1 11.56, 71 .03, 28.08, 10.29, DEPT spectrum: quaternary carbons δ 149.32, 146.19, 131.46, 125.33, 1 18.27; CH carbons δ 127.73, 126.8, 124.44, 1 19.88, 112.91 , 1 11.56, 71.03, CH2 carbon δ 28.08; CH3 carbon δ 10.29; IR (drifts) 3292 (s), 3038 (m), 2975 (m), 1621 (s), 1331 (s), 1320 (s), 1 1 14 (vs); Anal. Calcd for C16H15N4F3: C, 59.99; H, 4.72; N, 17.49. Found (first crop): C, 60.16; H, 4.74; N, 17.86. Found (second crop): C, 59.97; H, 4.66; N, 17.63.
Example 3 cιs-(2-Ethyl-6-trιfluoromethyl-1 ,2,3,4-tetrahvdro-quιnolιn-4-yl)-carbamιc acid benzyl ester A one liter, four neck flask under nitrogen atmosphere was charged with N-vinyl- carbamic acid benzyl ester (27.66 g, 156 mmol, 1.0 equiv) and dry toluene (500 mL). (1-Benzotrιazol-1-yl-propyl)-(4-trifluoromethyl-phenyl)-amιne (50.0 g, 156 mmol, 1.0 equiv) and p-toluenesulfonic acid monohydrate (297 mg, 1.56 mmol, 0 01 equiv) were added, and the mixture heated to 70°C. After 2 h, the mixture was cooled to room temperature and transfered to a separatory funnel. Ethyl acetate (500 mL) was added. The mixture was washed 1 x 200 mL 1 N NaOH, 1 x 200 mL H2O, 1 x 200 mL brine, and dried (MgSO4). The mixture was filtered and the solids washed 1 x 50 mL ethyl acetate. The filtrate was concentrated to approximately 250 mL. 500 mL toluene were added, and the mixture concentrated to approximately 500 mL. 500 mL n-heptane were added, the slurry was stirred 1 h, filtered through a Buchner funnel, and dried. cιs-(2-Ethyl-6-tπfluoromethyl-1 ,2,3,4-tetrahydro-quιnolιn-4-yl)-carbamιc acid benzyl ester was isolated as a white powder (45.04 g, 76%): mp 155-157 °C; 1H NMR (DMSO-d6, 400 MHz) δ 0.92 (t, 3H, J=7.5 Hz), 1.5 (m, 3H), 2.00 (m, 1 H), 3.35 (m, 1 H), 4.77 (m, 1 H), 5.07 (d, 1 H, J=12.5 Hz), 5.15 (d, 1 H, J=12.5 Hz), 6.35 (s, 1 H), 6.61 (d, 1 H, J=8.5 Hz), 7.12 (s, 1 H), 7.18 (dd, 1 H, J=1 .9, 8.5 Hz), 7.4 (m, 5H), 7.70 (d, 1 H, J=9.1 Hz); 13C NMR (DMSO-d6, 100 MHz) δ 157.03, 149.02, 137.79, 128.82, 128.23, 128.03, 125.9 (q, J=270 Hz), 125.06, 123.50, 121.73, 1 15.2 (q, J=31 7 Hz), 113.33, 65.85, 52.09, 47.83, 34.02, 28.68, 9.93; DEPT spectrum: quaternary carbons δ 157.03, 149.02, 137.79, 125.9, 121.73, 1 15.2, CH carbons δ 128.82,
128.23, 128.03, 125.06, 123.50, 1 13.33, 52.09, 47.83; CH2 carbons δ 65.85, 34.02, 28.68; CH3 carbon δ 9.93; IR (drifts) 3430 (m), 3303 (s), 2951 (m), 1686 (vs), 1542 (vs), 1088 (vs); MS (APCI+) m/z (rel. intensity) 379 (M+H\ 53), 228 (100); Anal. Calcd for C2oH2iN2O2F3: C, 63.48; H, 5.59; N, 7.40; Found. C, 63.69; H, 6.06, N, 7.36.
Example 4 cιs-4-Benzyloxycarbonylamιno-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 - carboxylic acid ethyl ester A three liter, four neck flask under nitrogen atmosphere was charged with cιs-(2- ethyl-6-trιfluoromethyl-1 ,2,3,4-tetrahydro-quιnolιn-4-yl)-carbamιc acid benzyl ester (96.0 g, 254 mmol, 1.0 equiv), dry dichloromethane (720 mL), and dry pyndine (103 mL, 1.27 mol, 5.0 equiv). A solution of ethyl chloroformate (121 mL, 1.27 mol, 5.0 equiv), in dry dichloromethane (240 mL), was added slowly over 4 h. The addition was exothermic and required a reflux condenser. Once the chloroformate addition was complete, the reaction was cooled in an ice bath and 1350 mL 1 N NaOH were added. The mixture was stirred 15 min, then transferred to a separator funnel. The layers were separated and the aqueous extracted 1 x 1 L dichloromethane. The combined dichloromethane layers were washed 1 x 1350 mL 1 N HCI, 1 x 1 L saturated aq. NaHCO3, 1 x 1 L brine, and dried (Na2SO4). The mixture was filtered, and the filtrate concentrated to an orange oil. 570 mL abs. ethanol were added, and the solution was concentrated. The solids were dissolved in 1370 mL abs. ethanol. 570 mL H2O were added dropwise over 45 mm. The resultant thick slurry was stirred 18 h and filtered. The solids were washed with cold 7:3 abs. ethanol/water (1 x 250 mL, then 1 x 100 mL) and dried (vac oven, 45°C) to give cιs-4- benzyloxycarbonylamιno-2-ethyl-6-tnfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 - carboxy c acid ethyl ester as a white, crystalline solid (94.54 g, 83%)- mp 92-96°C; 1H NMR (CDCI3, 400 MHz) δ 0.84 (t, 3H, J=7.4 Hz), 1.28 (t, 3H, J=7.0 Hz), 1.4 (m, 2H), 1.62 (m, 1 H), 2.53 (m, 1 H), 4.23 (m, 2H), 4.47 (m, 1 H), 4.79 (m, 1 H), 5.01 (d, 1 H, J=9.2 Hz), 5.18 (m, 2H), 7.4 (m, 5H), 7.5 (m, 2H), 7.57 (m, 1 H); 3C NMR (CDCI3, 100 MHz) δ 155.97, 154.43, 139.44, 136.21 , 134.33, 128.61 , 128.33, 128.22, 126.32 (q, J=31.7 Hz), 126.18, 124.22, 124.19, 124.12 (q, J=273 Hz), 120.74, 120.70, 67.22, 62.24, 53.47, 46.79, 37.75, 28.25, 14.38, 9.78; DEPT spectrum: quaternary carbons δ 155.97, 154.43, 139.44, 136.21 , 134.33, 126.32, 124.12; CH carbons δ 128.61 ,
128.33, 128.22, 126.18, 124.22, 124.19, 120.74, 120.70, 53.47, 46.79; CH2 carbons δ 67.22, 62.24, 37.75, 28.25; CH3 carbons δ 14.38, 9.78; IR (drifts) 3304 (s), 3067 (m), 3033 (m), 2982 (m), 2932 (m), 1723 (s), 1693 (s), 1545 (s); MS (APCI+) m/z (rel. intensity) 451 (M+H+, 2), 300 (100); Anal. Calcd for C23H25N2O4F3: C, 61.33; H, 5.60; N, 6.22. Found: C, 61.07; H, 5.69; N, 6.22.
Example 5 cis-4-Amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid ethyl ester A one liter, four neck flask under nitrogen atmosphere was charged with cis-4- benzyloxycarbonylamino-2-ethyl-6-thfluoromethyl-3,4-dihydro-2H-quinoline-1 - carboxylic acid ethyl ester (40.1 g, 89 mmol, 1.0 equiv), methanol (400 mL), and ammonium formate (14.0 g, 223 mmol, 2.5 equiv). 10% Pd/C, 50% water wet (4.0 g) was added, and the slurry heated to 40° C over 1 h. After 1.5 h, the mixture was cooled to room temperature and filtered through Celite®. The cake was washed 2 x 100 mL methanol. The filtrate was concentrated to approximately 75 mL, transferred to a separatory funnel, and diluted with 400 mL ethyl acetate. The mixture was washed 1 x 125 mL saturated aq. NaHCO3, 1 x 100 mL brine, and dried (Na2SO ). The mixture was filtered and the filtrate concentrated to a clear oil. The oil was crystallized from 100 mL n-heptane to give cis-4-amino-2-ethyl-6-trifluoromethyl-3,4- dihydro-2H-quinoline-1 -carboxylic acid ethyl ester as a white crystalline solid (26.05 g, 93%): mp 61.5-63.5° C; 1H NMR (CDCI3, 400 MHz) δ 0.79 (t, 3H, J=7.5 Hz), 1.24 (m, 4H), 1.42 (m, 1 H), 1.51 (br s, 2H), 1.62 (m, 1 H), 2.46 (m, 1 H), 3.73 (m, 1 H), 4.17 (m, 2H), 4.36 (m, 1 H), 7.44 (m, 2H), 7.66 (m, 1 H); 13C NMR (CDCI3, 100 MHz) δ 154.6, 139.3, 138.9, 126.3 (q, J=32 Hz), 125.7, 124.3 (q, J=271 Hz), 123.5, 119.8, 61.96, 54.16, 46.91 , 41.50, 28.85, 14.38, 9.60; DEPT spectrum: quaternary carbons δ
154.6, 139.3, 138.9, 126.3, 124.3; CH carbons δ 125.7, 123.5, 1 19.8, 54.16, 46.91 ; CH2 carbons δ 61.96, 41.50, 28.85; CH3 carbons δ 14.38, 9.60; IR (drifts) 3350 (s), 3293 (m), 2972 (s), 1697 (vs); MS (ES+) m/z (rel. intensity) 358 (M+H+CH3CN\ 55), 317 (M+H+, 7), 300 (100); Anal. Calcd for C15H19N2O2F3: C, 56.96; H, 6.06; N, 8.86. Found: C, 56.86; H, 6.28; N, 8.82.
Example 6 (-) (2R, 4S)-4-Amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid ethyl ester hemi-(-)-dibenzoyl-L-tartrate salt
A one liter flask under nitrogen atmosphere was charged with cιs-4- benzyloxycarbonylamιno-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 - carboxylic acid ethyl ester (24.0 g, 75.9 mmol, 1.0 equiv) and (-) dibenzoyl-L-tartaric acid (anhydrous) (27.19 g, 75.9 mmol, 1.0 equiv) 300 mL of approximately 97% ethanol (prepared by adding 10.5 mL H2O to 500 mL absolute ethanol, mixing, and measuring out 300 mL) was added. The mixture was stirred at room temperature for 18 h, then filtered. The solids were washed 1 x 48 mL approximately 97% ethanol, and dried to give (-) (2R, 4S)-4-amιno-2-ethyl-6-tπfluoromethyl-3,4-dιhydro-2H- quιnolιne-1 -carboxylic acid ethyl ester hemι-(-)-dιbenzoyl-L-tartrate salt as a white crystalline solid (14.77 g, 39%): mp 189.5-191.5 °C (dec); 1H NMR (DMSO-d6, 400 MHz) δ 0.62 (t, 3H, J=7.3 Hz), 1.16 (t, 3H, J=7.1 Hz), 1.3 (m, 3H), 2.5 (m, 1 H), 4.1 (m, 4H), 5.63 (s, 1 H, methine proton in DBTA), 7.47 (m, 2H, DBTA aromatic H's), 7.6 (m, 3H, DBTA aromatic H's), 7.68 (s, 1 H), 7.95 (m, 2H), 8.2 (br s, NH3 +, did not integrate); 13C NMR (DMSO-d6, 100 MHz) δ 169.85, 165.53, 154.10, 140.14, 134.59, 133.51 , 130.74, 129.69, 128.98, 126.74, 124.82 (q, J=31.7 Hz), 124.69 (q, J=271 Hz), 124.50, 120.90, 74.49, 62.14, 53.51 , 45.94, 38.81 , 28.23, 14.63, 9.58; DEPT spectrum: quaternary carbons δ 169.85, 165.53, 154.10, 140.14, 134.59, 130.74, 124.82, 124.69; CH carbons δ 133.51 , 129.69, 128.98, 126.74, 124.50, 120.90, 74.49, 53.51 , 45.94; CH2 carbons δ 62.14, 38.81 , 28.23; CH3 carbons δ 14.63, 9.58, IR (drifts) 3278 (m), 2400-3100 (broad), 1703 (vs); MS (ES+) m/z (rel. intensity) 358 (M+H+CH3CN+, 55), 317 (M+H+, 7), 300 (100); Anal Calcd for C15H19N2O2F3.C9H7O4. C, 58.18; H, 5.29; N, 5.65. Found. C, 57.99, H, 5.15; N, 5.64, Chiral HPLC: mobile phase 950-50:2 n-hexane:2-propanol:HOAc, flow rate 1.50 mLVmin, column temp 40°C, chiralpak™ AD 4.6 x 250 mm, sample concentration approximately 0 5 mg/mL in approximately 1 :1 n-hexane:2-propanol. Authentic racemate shows retention times of 7.5 mm and 10.0 mm. (-) (2R, 4S)-4-Amιno-2-ethyl-6-tπfluoromethyl-3,4-dιhydro- 2H-quιnolιne-1 -carboxylic acid ethyl ester hemι-(-)-dιbenzoyl-L-tartrate salt: 10 0 mm, 88.9%, 7.5 mm «1 %, 2.0 mm (solvent front) 1 1 1 %; [α]D = -153 (c=1.07, CH3OH)
Example 7 (-H2R, 4S)-4-(3,5-Bιs-trιfluoromethyl-benzylamιno)-2-ethyl-6-tπfluoromethyl-3,4- dιhydro-2H-guιnolιne-1 -carboxylic acid ethyl ester tosylate salt (-) (2R, 4S)-4-Amιno-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester hemι-(-)-dιbenzoyl-L-tartrate salt (13 0 g, 26 2 mmol, 1 0 equiv) was
suspended in 1 ,2-dιchloroethane (260 mL) in a 500 mL separatory funnel. The mixture was washed 1 x 65 mL 1 N NaOH, 1 x 65 mL brine, and dried (MgS04). The mixture was filtered, concentrated to approximately approximately 80 mL, and transferred to a 250 mL three neck flask. 3,5-Bιs(trιfluoromethyl)benzaldehyde (4.53 mL, 27.5 mmol, 1.05 equiv) was added, and the mixture stirred 1 h at room temperature under nitrogen atmosphere. Sodium triacetoxyborohydπde (11.1 g, 52.4 mmol, 2.0 equiv) was added in one portion, and the white slurry was stirred 18 h. 50 mL 1 ,2-dιchloroethane and 50 mL 2N NaOH were added, and the aqueous layer extracted 2 x 50 mL 1 ,2-dιchloroethane. The combined organic extracts were washed 1 x 31 mL 1 N HCI, 1 x 50 mL saturated aq. NaHCO3, 1 x 50 mL brine, and dried (Na2SO4). The mixture was filtered and concentrated to a clear oil. The oil was dissolved in methanol (71 mL). p-Toluenesulfonic acid monohydrate (5.23 g, 27.5 mmol, 1.05 equiv) was added. After 5 mm, 284 mL isopropyl ether was added. The solution was concentrtated to approximately 35mL, transferred to a 500 mL three neck flask (mech. stirrer), and diluted with 284 mL isopropyl ether. A thick white slurry formed in 10 minutes. After stirring 3 h, the slurry was filtered and the cake washed 2 x 70 mL isopropyl ether. After drying, (-)-(2R, 4S)-4-(3,5-bιs- trifluoromethyl-benzylamιno)-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 - carboxyhc acid ethyl ester tosylate salt was isolated as a white powder (16.18 g, 86% overall): mp 191 -192°C; 1H NMR (DMSO-d6, 400 MHz) δ 0.78 (t, 3H, J=7.5 Hz), 1.21 (t, 3H, J=7.0 Hz), 1.5 (m, 3H), 2.24 (s, 3H), 3.08 (m, 1 H), 4.17 (m, 2H), 4.41 (m, 1 H), 4.50 (m, 2H), 4.79 (m, 1 H), 7.04 (d, 2H, J=7.9 Hz), 7.42 (d, 2H, J=7.9 Hz), 7.7 (m, 2H), 7.81 (s, 1 H), 8.21 (s, 1 H), 8.35 (s, 2H), 9.58 (br s, 1 H), 9.83 (br s, 1 H); 3C NMR (DMSO-d6, 100 MHz) δ 154.00, 145.46, 140.21 , 138.39, 135.33, 132.51 , 131.62, 130.79 (q, J=33.2 Hz), 128.49, 127.40, 125.82, 125.36, 124.99 (q, J=31 .7 Hz),
124.59 (q, J=271 Hz), 123.69 (q, J=273 Hz), 123.44, 120.33, 62.32, 53.99, 53.79, 47.98, 33.30, 28.61 , 21.13, 14.63, 9.58; DEPT spectrum: quaternary carbons δ 154.00, 145.46, 140.21 , 138.39, 135.33, 130.79, 124.99, 124.59, 123.69; CH carbons δ 132.51 , 131.62, 128.49, 127.40, 125.82, 125.36, 123.44, 120.33, 53.99, 53.79; CH2 carbons δ 62.32, 47.98, 33.30, 28.61 ; CH3 carbons δ 21 13, 14 63, 9 58 IR (drifts) 2300-3100 (broad), 2974 (m), 2731 (m), 2620 (m), 2455 (m), 1714 (s), 1621 (m), 1283 (vs), 1 169 (vs), 1126 (vs), MS (ES+) m/z (rel. intensity) 584 (M+H+CH3CN+, 100), 543
C, 52 11 , H, 4.37; N,
3.92. Found: C, 52.15; H, 4.22; N, 3.69; [α]D = -77.9 (c = 1.05, CH3OH)
Example 8 (-H2R, 4S)-4-[(3,5-Bιs-tπfluoromethyl-benzyl)-methoxycarbonyl-amιno1-2-ethyl-6- trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester mono ethanolate Na2CO3 (s) (6.75 g, 63.7 mmol, 3.5 equiv) was added to a room temperature solution of (-)-(2R, 4S)-4-(3,5-bιs-trιfluoromethyl-benzylamιno)-2-ethyl-6-trιfluoromethyl-3,4- dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester tosylate salt (13.0 g, 18.2 mmol, 1.0 equiv) in dry THF (130 mL). Methyl chloroformate (3.51 mL, 45.5 mmol, 2.5 equiv) was added neat, dropwise over 2 mm. After 24 h, the mixture was concentrated to 65 mL, diluted with 260 mL ethyl acetate, and transferred to a separately funnel. The mixture was washed 1 x 90 mL 1 N HCI (C02 evolution), 1 x 90 mL saturated aq. NaHCO3, 1 x 90 mL brine, and dried (MgSO4). Filtration and concentration of filtrate afforded a clear oil, which was costπpped 3 x 33 mL 2B ethanol. The oil was dissolved in 33 mL 2B ethanol and seeded with a few milligrams of (-)-(2R, 4S)-4-[(3,5-bιs-tπfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6- trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester mono ethanolate. After stirring 18 h at room temperature, the slurry was filtered and dried to give (-)-(2R, 4S)-4-[(3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2- ethyl-6-trifluoromethyl-3,4-dihydro-2H-quιnolιne-1 -carboxylic acid ethyl ester mono ethanolate as a white crystalline powder (8.66 g, 74%): mp 54-58 °C; 1H NMR
(CDCI3, 400 MHz, 55°C) δ 0.73 (t, 3H, J=7.0 Hz), 1.20 (t, EtOH), 1.27 (t, 3H, J=7.1 Hz), 1.42 (m, 2H), 1.66 (m, 1 H), 2.25 (br s, 1 H), 3.67 (q, EtOH), 3.79 (s, 3H), 4.2 (m, 3H), 4.33 (m, 1 H), 5.2 (br s, 2H), 7.12 (s, 1 H), 7.49 (d, 1 H, J=8.3 Hz), 7.57 (d, 1 H, J=8.5 Hz), 7.73 (s, 2H), 7.78 (s, 1 H); 13C NMR (CDCI3, 400 MHz) δ 157 74, 154.37, 141.73, 140.05, 133.83, 132.14 (q, J=33 Hz), 126.94, 124.49, 123.96 (q, J=273 Hz), 123.13 (q, J=273 Hz), 121.31 , 1 19.17, 62.29, 58.28, 54.42, 53 71 , 53.08, 46.67, 37.01 , 29.02, 18.29, 14.32, 9.22, (note: the fourth quartet appears to be buried under the δ 126.94 peak, with J approximately 32 Hz), DEPT spectrum: quaternary carbons δ 157.74, 154.37, 141.73, 140.05, 133.83, 132 14, 123.96, 123.13; CH carbons δ 126.94, 124.49, 121.31 , 1 19 17, 54.42, 53.08; CH2 carbons δ 62.29, 58.28, 46.67, 37.01 , 29.02; CH3 carbons δ 53.71 , 18.29, 14.32, 9.22; IR (drifts) 3489 (s), 2974 (s), 2884 (m), 1701 (vs), 1280 (vs), 1 131 (vs); MS (ES+) m/z (rel. intensity) 601 (M+H+, 100); Anal. Calcd for
C, 52.01 ; H, 4.83; N, 4.33 Found: C,
51.84; H, 4.54; N, 4.33; chiral HPLC: mobile phase 950.50 2 n-hexane:2- propanol HOAc, flow rate 1.0 mLVmin, 254 nm, chiralpak AD 4.6 x 250 mm, column temp 40°C, sample concentration approximately 0.5 mg/mL in 90:10 n-hexane:2- propanol, authentic racemate retention times 3.6 and 4.6 mm (-)-(2R, 4S)-4-[(3,5-Bιs- trιfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro- 2H-quιnolιne-1 -carboxylic acid ethyl ester mono ethanolate shows 4.6 mm, 99.1 % and 3.6 mm, not detected; [α]D = -93.3 (c = 1 .08, CH3OH).
Example 9 Anhydrous, (-)-(2R,4S)-4-[(3,5-Bιs-trιfluoromethyl-benzyl)-methoxycarbonyl-amιnol-2- ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester.
A 2.6g portion of 4(S)-[(3,5-bιs-tπfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2(R)- ethyl-6-tπfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester (a mixture of predominantly amorphous material with traces of ethanolate crystalline form; the title compound was also prepared in an analogous manner starting from pure amorphous or pure ethanolate material) was charged to 13 milliliters of hexanes and heated to effect a solution at about 60°C The heat was removed and the reaction was allowed to cool to ambient over a one hour period The reaction was seeded with anhydrous (-)-(2R,4S)-4-[(3,5-bιs-tπfluoromethyl-benzyl)- methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 - carboxylic acid ethyl ester and granulated for eighteen hours under ambient conditions. Alternately, the anhydrous crystals may be prepared from hexanes without seeding. The product was collected by filtration and air dried. The isolated product X-ray pattern matched the calculated powder pattern. Density: 1.406 Crystal System: Trigonal
Microscopy: Well formed rods and equant (fractured rods) crystals demonstrating high birefringence when viewed across the C axis. Being in the Trigonal crystal system the crystals do not demonstrate birefringence when viewed down the C axis. The crystals demonstrate a cleavage plane perpendicular to the C axis Fusion Microsocopy In Type A oil dissolution at 50°C.
Dry — clear melt at 86°C.
NMR: No trace of ethanolate
Degree of crystallmity: Highly crystalline
Hygroscopicity. Non-hygroscopic at 100% relative humidity over 48 hours.
Appearance: Free flowing white powder.
The X-Ray diffraction d-spacing is provided in Table 2
TABLE 2
Example 10
Monoethanolate, (-)-(2R,4S)-4-[(3,5-Bιs-trιfluoromethyl-benzyl)-methoxycarbonyl- amιnol-2-ethyl-6-trιfluoromethyl-3,4-dιhvdro-2H-guιnolιne-1 -carboxylic acid ethyl ester.
4.0 grams of (-)-(2R,4S)-4-[(3,5-bιs-tπfluoromethyl-benzyl)-methoxycarbonyl-amιno]-
2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester_were dissolved in 3.5 ml ethanol and sonicated for two minutes to complete dissolution. A white solid formed to which 10 ml ethanol was added and stirred at ambient temperature overnight. A white powder was filtered and collected on 0.22 μm LS filter paper followed by washing with about 15 ml. ethanol. The isolated product X-ray pattern matched the calculated powder pattern.
Density: 1 .402 Crystal System: orthorhombic
Microscopy: crystalline needles with moderate birefringence.
Fusion Microsocopy: In Type A oil melt and dissolution at 43°C with loss of water
Dry clear melt at 43°C
NMR: shows ethanol of solvation Degree of crystal nity: highly crystalline
Hygroscopicity: non-hygroscopic
Appearance: free-flowing white power The X-Ray diffraction d-spacing is provided in Table 3.
TABLE 3
Anode: CU - Wavelength 1 ■ 1.54056 Wavelength 2' 1 .54439 (Rel Intensity: 0.500) Range #1 - Coupled: 3.000 to 40.000 StepSize: 0.040 StepTime: 1.00 Smoothing Width: 0.300 Threshold: 1.0
Example 11 Anhydrous (-)-(2R,4S)-4-[(3,5-bιs-trιfluromethylbenzyl)-methoxycarbonyl-amιnol-2- ethyl-6-trιfluoromethyl-3,4-dιhvdro-2H-guιnolιne-1 -carboxylic acid ethyl ester. A crude solution of approximately 42 g of (-)-(2R,4S)-4-[(3,5-bιs-tπfluromethylbenzyl)- methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 - carboxylic acid ethyl ester in 500 ml of ethyl acetate (obtained via the process described in Example 8) was concentrated under vacuum to a volume of 100-135 ml. The remaining ethyl acetate was displaced with 3 X 220 ml 2B EtOH to a final volume
of 100-135 ml. This solution was seeded with a crystal of anhydrous (-)-(2R,4S)-4- [(3,5-bιs-trιfluromethylbenzyl)-methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4- dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester. After stirring 18 hr at room temperature the slurry was filtered and vacuum dried to give 19.81 g of anhydrous (-)- (2R,4S)-4-[(3,5-bιs-trιfluromethylbenzyl)-methoxycarbonyl-amιno]-2-ethyl-6- trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester. The melting point behaviour was the same as the material prepared via Example 9 confirming the anhydrous nature of the material.
Claims
A crystalline form of the compound of formula I
2. A crystal which is anhydrous [2R,4S] 4-[(3,5-bιs-trιfluoromethyl-benzyl)- methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 - carboxyhc acid ethyl ester.
3 A crystal which is the ethanolate of [2R,4S] 4-[(3,5-bιs-tπfluoromethyl-benzyl)- methoxycarbonyl-amιno]-2-ethyl-6-tπfluoromethyl-3,4-dιhydro-2H-quιnolιne-1 - carboxylic acid ethyl ester
4. A crystal of claim 1 which is the anhydrous crystal having the x-ray powder diffraction d-spacing
5 A crystal of claim 1 which is the ethanolate crystal having the x-ray powder diffraction d-spacing
Anode: CU - Wavelength 1 : 1.54056 Wavelength 2: 1 .54439 (Rel Intensity: 0.500) Range #1 - Coupled: 3.000 to 40.000 StepSize: 0.040 StepTime. 1.00 Smoothing Width: 0.300 Threshold: 1.0
6. A pharmaceutical composition which comprises a therapeutically effective amount of a crystal of claim 1 and a pharmaceutically acceptable carrier, vehicle or diluent. 7. The pharmaceutical composition as recited in claim 6 wherein the pharmaceutical composition comprises an atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertπglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular
comphcations of diabetes, obesity or endotoxemia treating amount of the crystal of claim 1 and a pharmaceutically acceptable carrier, vehicle or diluent 8 The pharmaceutical composition as recited in claim 6 for the treatment of atherosclerosis which comprises an atherosclerosis treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent 9. The pharmaceutical composition as recited in claim 8 wherein the atherosclerosis treating amount of the Formula I crystal is about 0 1 to 10 mg/kg/day, and the pharmaceutical composition was prepared by dissolving the crystal of claim 1 in a fatty oil 10. The pharmaceutical composition as recited in claim 8 wherein the Formula I crystal is anhydrous.
1 1. The pharmaceutical composition as recited in claim 8 wherein the Formula I crystal is the ethanolate crystal
12. A method of inhibiting CETP in a mammal in need thereof which comprises the administration of a CETP inhibiting amount of the Formula I crystal as recited in claim 1.
13. The method as recited in claim 12 comprising treating atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertπglyceridemia, familial- hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia by administering to a mammal, in need of such treatment a therapeutically effective amount of the Formula I crystal. 14 The method as recited in claim 13 wherein atherosclerosis is treated with an atherosclerosis treating amount of the Formula I crystal 15. The method as recited in claim 14 wherein the atherosclerosis treating amount of the Formula I crystal is about 0.1 to 10 mg/kg/day and the Formula I crystal was dissolved in a fatty oil 16 The method as recited in claim 15 wherein the Formula I crystal is anhydrous
17 The method as recited in claim 15 wherein the Formula i salt is the ethanolate.
18 A process for preparing crystalline anhydrous [2R,4S] 4-[(3,5-bιs- trιfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6-tπfluoromethyl-3,4-dιhydro-
2H-quιnolιne-1 -carboxylic acid ethyl ester comprising dissolving or mixing [2R,4S] 4- [(3,5-bιs-tπfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4- dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester in hexanes at ambient temperature for about 2 to about 24 hours wherein said precursor is not an anhydrous crystalline form
19 A process for preparing crystalline ethanolate [2R,4S] 4-[(3,5-bιs- tπfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro- 2H-quιnolιne-1 -carboxylic acid ethyl ester by dissolving or mixing [2R,4S] 4-[(3,5-bιs- tπfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro- 2H-quιnolιne-1 -carboxylic acid ethyl ester in ethanol/water at ambient temperature for about 0 5 to about 18 hours wherein said precursor is not a crystalline ethanolate form
20 The process as recited in claim 19 wherein ethanol is used without water
21 A process for preparing crystalline anhydrous [2R,4S] 4-[(3,5-bιs- tπfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4-dιhydro- 2H-quιnolιne-1 -carboxylic acid ethyl ester comprising dissolving or mixing [2R,4S] 4- [3,5-bιs-trιfluoromethyl-benzyl)-methoxycarbonyl-amιno]-2-ethyl-6-trιfluoromethyl-3,4- dιhydro-2H-quιnolιne-1 -carboxylic acid ethyl ester in ethanol at ambient temperature for about 2 to about 24 hours wherein said precursor is not an anhydrous crystalline form
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16805199P | 1999-11-30 | 1999-11-30 | |
| US168051P | 1999-11-30 | ||
| PCT/IB2000/001650 WO2001040190A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1246804A1 true EP1246804A1 (en) | 2002-10-09 |
Family
ID=22609901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00971662A Withdrawn EP1246804A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1246804A1 (en) |
| JP (1) | JP2003515592A (en) |
| KR (1) | KR20020058057A (en) |
| CN (1) | CN1402711A (en) |
| AP (1) | AP2002002531A0 (en) |
| AU (1) | AU1048801A (en) |
| BG (1) | BG106854A (en) |
| BR (1) | BR0015836A (en) |
| CA (1) | CA2392979A1 (en) |
| CO (1) | CO5271716A1 (en) |
| EA (1) | EA200200510A1 (en) |
| EC (1) | ECSP003792A (en) |
| EE (1) | EE200200277A (en) |
| GT (1) | GT200000199A (en) |
| HU (1) | HUP0203521A2 (en) |
| IL (1) | IL149097A0 (en) |
| IS (1) | IS6338A (en) |
| MA (1) | MA26845A1 (en) |
| MX (1) | MXPA02005354A (en) |
| NO (1) | NO20022558D0 (en) |
| OA (1) | OA12099A (en) |
| PA (1) | PA8506301A1 (en) |
| PE (1) | PE20010904A1 (en) |
| PL (1) | PL355892A1 (en) |
| TN (1) | TNSN00231A1 (en) |
| TR (1) | TR200201446T2 (en) |
| UY (1) | UY26454A1 (en) |
| WO (1) | WO2001040190A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| EA200301139A1 (en) | 2001-06-21 | 2004-12-30 | Пфайзер Продактс Инк. | SELF-EMULATING PREPARATIONS OF THE INHIBITORS OF CHOLESTEROL ETHERUM PROTECTIVE |
| GT200200170A (en) | 2001-09-28 | 2003-05-23 | PREPARATION OF INHIBITOR OF CETP ANHIDRO | |
| DE60320940D1 (en) | 2002-02-01 | 2008-06-26 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DISPERSIONS OF ACTIVE SUBSTANCES AND LIPOPHILIC MICROPHASE-BASED MATERIALS |
| PL372247A1 (en) * | 2002-02-01 | 2005-07-11 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
| US7332514B2 (en) | 2002-08-30 | 2008-02-19 | Japan Tobacco Inc. | Dibenzylamine compound and medicinal use thereof |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| WO2004032848A2 (en) | 2002-10-04 | 2004-04-22 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| JP2006513186A (en) | 2002-12-20 | 2006-04-20 | ファイザー・プロダクツ・インク | Dosage form comprising CETP inhibitor and HMG-COA reductase inhibitor |
| WO2004082675A1 (en) | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate |
| JP2006521344A (en) * | 2003-03-28 | 2006-09-21 | ファイザー・プロダクツ・インク | 1,2,4-substituted 1,2,3,4-tetrahydro- and 1,2-dihydro-quinoline and 1,2,3,4 as CETP inhibitors for the treatment of atherosclerosis and obesity -Tetrahydro-quinoxaline derivatives |
| BRPI0413277A (en) | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | pharmaceutical compositions of amorphous drug adsorbates and lipophilic microphase forming materials |
| DE602004023100D1 (en) | 2003-10-08 | 2009-10-22 | Lilly Co Eli | COMPOUNDS AND METHOD FOR THE TREATMENT OF DYSLIPIDEMY |
| CA2562082C (en) * | 2004-04-13 | 2013-06-25 | Merck & Co., Inc. | Cetp inhibitors for the treatment and prevention of atherosclerosis |
| EA200700119A1 (en) * | 2004-06-24 | 2007-10-26 | Эли Лилли Энд Компани | CONNECTIONS AND METHODS OF TREATMENT OF DYSLIPIDEMIA |
| WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
| WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
| WO2006091674A1 (en) | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| WO2006098394A1 (en) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Method for inhibiting lipid absorption and lipid absorption inhibitor |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| CL2008000684A1 (en) | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION THAT INCLUDES METFORMIN R - (+) LIPOATE AND A HMG-COA REDUCTASE INHIBITOR; UNIT DOSE FORMULATION; AND USE IN THE TREATMENT OF A DIABETIC COMPLICATION. |
| EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| TWI450896B (en) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
| MX384679B (en) | 2014-07-30 | 2025-03-14 | Hoffmann La Roche | GENETIC MARKERS TO PREDICT REACTIVITY TO THERAPY WITH A HIGH-DENSITY LIPOPROTEIN (HDL)-ELEVATING OR HIGH-DENSITY LIPOPROTEIN (HDL-MIMICKING AGENT. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| AU5731098A (en) * | 1997-02-03 | 1998-08-25 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/en unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/en unknown
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/en not_active IP Right Cessation
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/en not_active Ceased
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/en unknown
- 2000-11-14 CN CN00816463A patent/CN1402711A/en active Pending
- 2000-11-14 IL IL14909700A patent/IL149097A0/en unknown
- 2000-11-14 EA EA200200510A patent/EA200200510A1/en unknown
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/en unknown
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/en unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/en active Pending
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Ceased
- 2000-11-14 EE EEP200200277A patent/EE200200277A/en unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/en not_active Application Discontinuation
- 2000-11-28 UY UY26454A patent/UY26454A1/en not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/en not_active Application Discontinuation
- 2000-11-29 GT GT200000199A patent/GT200000199A/en unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/en unknown
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/en unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/en unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/en unknown
- 2002-05-29 NO NO20022558A patent/NO20022558D0/en not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/en unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0140190A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20022558L (en) | 2002-05-29 |
| EA200200510A1 (en) | 2002-10-31 |
| WO2001040190A1 (en) | 2001-06-07 |
| BR0015836A (en) | 2002-08-06 |
| BG106854A (en) | 2002-12-29 |
| IS6338A (en) | 2002-04-12 |
| ECSP003792A (en) | 2002-04-23 |
| JP2003515592A (en) | 2003-05-07 |
| PL355892A1 (en) | 2004-05-31 |
| KR20020058057A (en) | 2002-07-12 |
| OA12099A (en) | 2006-05-04 |
| CO5271716A1 (en) | 2003-04-30 |
| UY26454A1 (en) | 2001-07-31 |
| AU1048801A (en) | 2001-06-12 |
| HUP0203521A2 (en) | 2003-02-28 |
| NO20022558D0 (en) | 2002-05-29 |
| PE20010904A1 (en) | 2001-09-10 |
| EE200200277A (en) | 2003-10-15 |
| GT200000199A (en) | 2002-05-23 |
| TR200201446T2 (en) | 2002-11-21 |
| MA26845A1 (en) | 2004-12-20 |
| MXPA02005354A (en) | 2002-12-11 |
| AP2002002531A0 (en) | 2002-06-30 |
| CA2392979A1 (en) | 2001-06-07 |
| TNSN00231A1 (en) | 2002-05-30 |
| IL149097A0 (en) | 2002-11-10 |
| CN1402711A (en) | 2003-03-12 |
| PA8506301A1 (en) | 2002-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1246804A1 (en) | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor | |
| EP1125929B1 (en) | Method for making (-)-(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester | |
| DE69917400T2 (en) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | |
| US5112817A (en) | Quinoline derivatives | |
| DE69917790T2 (en) | 4-AMINO SUBSTITUTED -2-SUBSITUTE-1,2,3,4-TETRAHYDROCHINOLINE AS CETP INHIBITORS | |
| DE69926582T2 (en) | Anellated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | |
| DE69925845T2 (en) | 4-CARBOXAMINO-2-SUBSITUTED-1,2,3,4-TETRAHYDROCHINOLINE AS CETP INHIBITORS | |
| DE69920727T2 (en) | 4-CARBOXAMINO-2-METHYL-1,2,3,4-TETRAHYDROCHINOLINE AS CETP INHIBITORS | |
| DE60211944T2 (en) | ACETYLENE DERIVATIVES WITH MGLUR 5 ANTAGONISTIC EFFECT | |
| JPH1067746A (en) | Cycloalkanolpyridine | |
| US5204348A (en) | Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components | |
| DE102004044680B3 (en) | Alkylidene tetrahydronaphthalene derivatives, process for their preparation and their use as anti-inflammatory agents and pharmaceutical compositions containing them | |
| CA2090635A1 (en) | Substituted phenylquinazoline derivatives | |
| HK1038007B (en) | Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline | |
| MXPA00011855A (en) | Method for making (-)-(2r,4s)-4- [(3,5-bis- trifluoromethyl-benzyl)- methoxycarbonylamino]- 2-ethyl-6- trifluoromethyl-3,4-dihydro- 2h-quinoline- 1-carboxylic acid ethyl ester |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020515 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20020515;LT PAYMENT 20020515;LV PAYMENT 20020515;MK PAYMENT 20020515;RO PAYMENT 20020515;SI PAYMENT 20020515 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20040602 |